




LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i>					ATTY. DOCKET NO.:	APPLICATION NO.:		
					87534-4300	10/764,288		
					APPLICANT:			
					Nurit LIVNAH et al.			
					FILING DATE:	GROUP:		
					January 23, 2004	1614		
U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME		CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AG	AA	6,034,097	3/2000	DiMaio et al.		514	308	
	AB							
	AC							
	AD							
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY		CLASS	SUBCLAS	TRANSLATION
								YES NO
AG	AE	WO 97/22360	6/1997	PCT				<input checked="" type="checkbox"/> X
	AF							
	AG							
	AH							
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)								
	AI							
	AJ							
	AK							
	AL							
EXAMINER				DATE CONSIDERED				
/Anish Gupta/				10/16/2006				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i>					ATTY. DOCKET NO.:	APPLICATION NO.:		
					87534-4300	10/764,288		
					APPLICANT:			
					Nurit LIVNAH et al.			
FILING DATE:					GROUP:			
January 23, 2004					1614			
U.S. PATENT DOCUMENTS								
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	AA							
	AB							
	AC							
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
	AD						YES	NO
	AE							
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)								
AG	AF	Dario R. Alessi et al., "Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase," <i>FEBS Letters</i> 399, pp. 333-338 (1996)						
	AG	Yi Fang et al., "Focal adhesion kinase affects the sensitivity of human hepatocellular carcinoma cell line SMMC-7721 to tumor necrosis factor- α /cycloheximide-induced apoptosis by regulating protein kinase B levels," <i>Eur. J. Biochem.</i> , vol. 268, pp. 4513-4519 (2001)						
	AH	Hiroyoshi Hidaka et al, "Isoquinolinesulfonamides, Novel and Potent Inhibitors of Cyclic Nucleotide Dependent Protein Kinase and Protein Kinase C," <i>Biochemistry</i> , vol. 23, pp. 5036-5041 (1984)						
	AI	Chandra C. Kumar et al., "Expression, purification, characterization and homology modeling of active Akt/PKB, a key enzyme involved in cell survival signaling," <i>Biochimica et Biophysica Acta</i> , vol. 1526, pp. 257-268 (2001)						
	AJ	Ai-xue Liu et al., "AKT2, a Member of the Protein Kinase B Family, Is Activated by Growth Factors, v-Ha-ras, and v-src through Phosphatidylinositol 3-Kinase in Human Ovarian Epithelial Cancer Cells," <i>Cancer Research</i> , vol. 58, pp. 2973-2977 (1998)						
	AK	Mart Loog et al., "Adenosine-5'-Carboxylic Acid Peptidyl Derivatives as Inhibitors of Protein Kinases," <i>Bioorganic & Medicinal Chemistry Letters</i> , vol. 9, pp. 1447-1452 (1999)						
↓	AL	Robert Martell et al., "Effects of Protein Kinase Inhibitors 1(5-Isoquinolinesulfonyl)-2-Methyl(piperazine Dihydrochloride (H-7) and N-[2-Guanidinoethyl]-5-Isoquinolinesulfonamide Hydrochloride (HA1004) on Calcitriol-Induced Differentiation of HL-60 Cells," <i>Biochemical Pharmacology</i> , vol. 37, pp. 635-640 (1988)						
AG	AM	Karleen Nicholson et al., "The protein kinase B/Akt signalling pathway in human malignancy," <i>Cellular Signalling</i> , vol. 14, pp. 381-395 (2002)						

AG	AN	Masakatsu Nishikawa et al., "1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine(H-7), A Potent Inhibitor of Protein Kinases, Inhibits the Differentiation of HL-60 Cells Induced by horbol Diester", <i>Life Sciences</i> , vol. 39, pp. 1101-1107 (1986)
	AO	Toshiyuki Obata et al., "Peptide and Protein Library Screening Defines Optimal Substrate Motifs for AKT/PKB*", <i>The Journal of Biological Chemistry</i> , vol. 275, no. 46, pp. 36108-36115 (2000)
	AP	Keykavous Parang et al., "Mechanism-based design of a protein kinase inhibitor," <i>Nature Structure Biology</i> , vol. 8, number 1, pp. 37-41 (2001)
	AQ	G. Perez-Tenorio et al., "Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients," <i>British Journal of Cancer</i> , vol. 86, pp. 540-545 (2002)
	AR	Ricouart et al., "Design of Potent Protein Kinase Inhibitors Using the Bisubstrate Approach," <i>J. Med. Chem.</i> , vol. 34, pp. 73-78 (1991)
	AS	Baljinder Salh et al., "Dysregulation of Phosphatidylinositol 3-Kinase and Downstream Effectors in Human Breast Cancer," <i>Int. J. Cancer</i> , vol. 98, pp. 148-154 (2002)
	AT	Martin Schlitzer et al., "Design, Synthesis and Early Structure - Activity Relationship of Farnesyltransferase Inhibitors Which Mimic Both the Peptidic and the Prenylic Substrate," <i>Biorganic & Medicinal Chemistry</i> , vol. 8, pp. 1991-2006 (2000)
	AU	Shuho Semba et al., "The in Vitro and in Vivo Effects of 2-(4-Morpholinyl)-8-phenylchromone (LY294002), a Specific Inhibitor of Phosphatidylinositol 3'-Kinase, in Human Colon Cancer Cells," <i>Clinical Cancer Research</i> , vol. 8, pp. 1957-1963 (2002)
	AV	V. Waldmann et al., "Absence of mutations in the pleckstrin homology (PH) domain of protein kinase B (PKB/Akt) in malignant melanoma" <i>Melanoma Research</i> , vol. 12, pp. 45-50 (2002)
AG	AW	Michael J. Zinda et al., "AKT-1, -2, and -3 are Expressed in Both Normal and Tumor Tissues of the Lung, Breast, Prostate, and Colon," <i>Clinical Cancer Research</i> , vol. 7, pp. 2475-2479 (2001)
EXAMINER		DATE CONSIDERED
/Anish Gupta/		10/16/2006